FGFR-IN-13 (compound III-30) is an irreversible covalent fibroblast growth factor receptor ( FGFR ) inhibitor. FGFR-IN-13 regulates endogenous FGFR1 ( IC 50 =0.20±0.02 nM) and FGFR4 ( IC 50 =0.40±0.03 nM) mediated signaling pathways by inhibiting the expression of key proteins.FGFR-IN-13 inhibits total-PARP and Bcl-2 protein expressions, and promote Cleaved-PARP and Bax protein expressions in a dose-dependent manner. FGFR-IN-13 has significant antitumor activity and oral activity.